SurgicEye GmbH will present its Solutions for Nuclear Medicine Guided Therapies during the annual meeting of the European Society of Nuclear Medicine (EANM) including the 3D surgical imaging for support in radio-guided surgery as well as its dose planing and dose monitoring solutions for radionuclide therapy Additionally, a new solution for treatment planning is presented. DosePlan – smart and time-saving dosimetry Visit us in the Pavilion – Hall X2, Booth No. 238 for a product demonstration or a refreshing drink while having a break.
In the recent issue of “Faszination Forschung”, the TUM magazine of cutting edge research an article highlighting that declipse®SPECT is the first in the OR used augmented reality visualization in medicine on a regular, clinical basis. The issue 20 of “Faszination Forschung” highlights different research and transnational projects including SurgicEye® around digitization in general. In Addition to the joint R&D efforts in augmented reality and mobile nuclear imaging solutions, CAMP and SurgicEye®’s joint interest in artificial intelligence and deep learning with medical (imaging) data, simulation, classification and decision and therapy support system, especially in radio-guided surgery and radio-nuclide therapy are key for future projects between one of international leading institutions in medical image processing and computer vision in medicine CAMP and world leading innovator in quality assurance and guidance in therapies in nuclear medicine SurgicEye GmbH. Read more: Beyond the Limits of our Eyes Nassir Navab develops augmented reality systems to make additional information available to surgeons during an operation.
What clinicians say
- Dr. Sergi Vidal SicartNuclear Medicine Specialist, Hospital Clínic Barcelona, SpainThe 3D declipseSPECT presents a potential tool in refining the excision margins of tumor in the ROLL technique. The possibility to observe the harvested tissue and the tracer activity within it offers a realistic view of the surgical procedure suited for the operating room.
- Dr. Omgo E. NiewegSurgeon, The Netherlands Cancer Institute Amsterdam, the NetherlandsThe innovative 3D declipseSPECT technology may make the sentinel node biopsy easier and more reliable. New technologies like 3D declipseSPECT will also open up lymphatic mapping to additional cancer types in locations with a more intricate anatomy and cancer types with more complex lymph drainage.
- Prof. Dr. Marion KiechleDirector of the Women’s Hospital Klinikum rechts der Isar Munich, GermanyThe declipse®SPECT technology and its intraoperative use for navigated sentinel lymph node dissection enables safer surgeries, and less invasive procedures. This can ensure a high quality outcome for every individual patient.
- Prof. Dr. René HornungHead of Department of Gynecology Kantonsspital St. Gallen, SwitzerlandThe 3D declipse®SPECT Laparoscopy technology opens new horizons to minimally invasive surgery in gynecologic oncology. Sentinel lymph node biopsy during laparoscopic procedures seems to be easily feasible and may in the near future become standard of care for cervical and endometrial cancers.